UBS analyst Matthew Weston maintained a Hold rating on AstraZeneca (AZN – Research Report) today and set a price target of £115.00. The ...

The company said, “In relation to the illegal drug importation allegations, in January 2025, AstraZeneca (AZN) received a Notice of Transfer to ...

Pharma giant AstraZeneca urged Britain to improve the environment for businesses in order to drive investment, days after it ...